Archivel Farma participated in the TBVI Symposium on therapeutic vaccination

By 02/02/2018Research

Dr Pere-Joan Cardona, inventor of RUTI® vaccine and Scientific Advisor of Archivel Farma, and Olga Rué, company’s CEO, participated in the symposium organized by the TuBerculosis Vaccine Initiative (TBVI), on January 30, focused on Therapeutic vaccination and host-directed (immuno) therapy against TB.

TBVI symposium, celebrated along with the TBVAC2020 annual meeting, took place in Les Diablerets, Switzerland. This yearly event was attended by over 140 participants from 70 research institutes, universities, companies, funding and technical agencies.

The program of the TBVI symposium allowed the participants to share the last developments in R&D on TB, which right now are especially focused on therapeutic vaccines. This area, where Archivel Farma has been a pioneer with RUTI®, arouses a growing interest among the research community.

TBVI is a non-profit foundation that facilitates the discovery and development of new, safe and effective TB vaccines. The TBVI consortium includes more than 50 partners from academia, research institutes and private industry in the TB vaccine field, among them the Institute for Health Science Research Germans Trias i Pujol (IGTP) that has been the main collaborator of Archivel Farma in the development of RUTI®.